James Campbell speaks with Proactive’s Elisha Newell about the company’s successful engineering run to produce large-scale quantities of clinical grade PAT-DX1. It Is believed that PAT-DX1 may have application across a wide range of cancers including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers. Campbell explains the company is now a step closer to clinical trial of the tumour-targeting PAT-DX1 after this second engineering run produced large-scale quantities of the antibody. The PAB CEO says that if the batch meets specifications, the manufactured PAT-DX1 antibody should supply sufficient PAT-DX1 for the company to conduct final pre-clinical toxicology studies in preparation for a proposed Phase 1 clinical trial in the second half of 2023.
- Forums
- ASX - By Stock
- Ann: PAT-DX1 Engineering Run Successfully Completed
[MEDIA] James Campbell speaks with Proactive’s Elisha Newell...
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAB (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
-0.001(11.1%) |
Mkt cap ! $16.46M |
Open | High | Low | Value | Volume |
0.8¢ | 0.8¢ | 0.8¢ | $1.28K | 160K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 494316 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 1426680 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 494316 | 0.008 |
20 | 5753441 | 0.007 |
9 | 2237680 | 0.006 |
8 | 3155992 | 0.005 |
5 | 4324000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 1426680 | 2 |
0.010 | 1400000 | 2 |
0.011 | 1610000 | 5 |
0.012 | 372407 | 3 |
0.013 | 990000 | 2 |
Last trade - 15.47pm 08/05/2024 (20 minute delay) ? |
Featured News
PAB (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online